CAM
CLDX icon

Capstone Asset Management’s Celldex Therapeutics CLDX Stock Holding History

Capstone Asset Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-452
Closed -$240K – 1886
2013
Q3 		$240K Buy
+452
New +$155K 0.01% 1771

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
SCA
SAC Capital Advisors Stamford, Connecticut $19.3B AUM 31.93% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Capstone Asset Management's CLDX Position: Q4 2013 in Review

Capstone Asset Management sold out of Celldex Therapeutics (CLDX) in Q4 2013, closing a stake of 452 shares — an estimated $240K sold.

Capstone Asset Management first reported a position in CLDX in Q3 2013 and held it in 1 quarter. The position peaked at $240K in Q3 2013. 162 funds tracked by Wall St. Rank hold CLDX as of Q4 2013.

  • Capstone Asset Management reported no remaining Celldex Therapeutics position as of Q4 2013 after selling out during the quarter.
  • Capstone Asset Management sold 452 Celldex Therapeutics shares in Q4 2013, an estimated $240K.
  • Capstone Asset Management first reported a position in Celldex Therapeutics in Q3 2013 and held it in 1 quarter.
  • Capstone Asset Management's Celldex Therapeutics position peaked at $240K in Q3 2013.
  • 162 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2013.

Based on Capstone Asset Management's 13F filing for Q4 2013, filed 4 Feb 2014.